Simply Wall St.
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside
📈
AI Sentiment
Highly Positive
8/10
- Home
- KYMR
as of 03-17-2026 3:41pm EST
$80.62
+$1.02
+1.28%
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 6.8B | IPO Year: | 2020 |
| Target Price: | $107.72 | AVG Volume (30 days): | 627.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | -23.83 |
| 52 Week Low/High: | $19.45 - $103.00 | Next Earning Date: | 05-18-2026 |
| Revenue: | $39,211,000 | Revenue Growth: | -16.70% |
| Revenue Growth (this year): | 16.05% | Revenue Growth (next year): | 4.79% |
| P/E Ratio: | -21.98 | Index: | N/A |
| Free Cash Flow: | -234340000.0 | FCF Growth: | N/A |
AI-Powered KYMR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.83%
76.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Kymera Therapeutics Inc. (KYMR)
Chadwick Jeremy G
Sell
Chief Operating Officer
KYMR Mar 11, 2026
Avg Cost/Share
$82.98
Shares
25,758
Total Value
$2,145,673.35
Owned After
68,052
Gollob Jared
Sell
Chief Medical Officer
KYMR Mar 4, 2026
Avg Cost/Share
$85.36
Shares
4,895
Total Value
$417,521.08
Owned After
119,018
Jacobs Bruce N.
Sell
Chief Financial Officer
KYMR Mar 4, 2026
Avg Cost/Share
$85.36
Shares
4,895
Total Value
$417,521.08
Owned After
234,472
Chadwick Jeremy G
Sell
Chief Operating Officer
KYMR Mar 4, 2026
Avg Cost/Share
$85.36
Shares
3,919
Total Value
$334,272.49
Owned After
68,052
Gollob Jared
Sell
Chief Medical Officer
KYMR Mar 2, 2026
Avg Cost/Share
$88.64
Shares
5,613
Total Value
$499,147.54
Owned After
119,018
Booth Bruce
Sell
Director
KYMR Mar 2, 2026
Avg Cost/Share
$90.13
Shares
81,866
Total Value
$7,378,582.58
Owned After
3,902,667
Jacobs Bruce N.
Sell
Chief Financial Officer
KYMR Mar 2, 2026
Avg Cost/Share
$88.64
Shares
7,576
Total Value
$673,709.54
Owned After
234,472
Chadwick Jeremy G
Sell
Chief Operating Officer
KYMR Mar 2, 2026
Avg Cost/Share
$88.64
Shares
2,039
Total Value
$181,321.64
Owned After
68,052
Mainolfi Nello
Sell
Chief Executive Officer
KYMR Feb 25, 2026
Avg Cost/Share
$91.65
Shares
30,000
Total Value
$2,707,812.59
Owned After
676,431
Esposito Pamela
Sell
Director
KYMR Feb 20, 2026
Avg Cost/Share
$87.58
Shares
2,500
Total Value
$218,270.01
Owned After
600
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Chadwick Jeremy G | KYMR | Chief Operating Officer | Mar 11, 2026 | Sell | $82.98 | 25,758 | $2,145,673.35 | 68,052 | |
| Gollob Jared | KYMR | Chief Medical Officer | Mar 4, 2026 | Sell | $85.36 | 4,895 | $417,521.08 | 119,018 | |
| Jacobs Bruce N. | KYMR | Chief Financial Officer | Mar 4, 2026 | Sell | $85.36 | 4,895 | $417,521.08 | 234,472 | |
| Chadwick Jeremy G | KYMR | Chief Operating Officer | Mar 4, 2026 | Sell | $85.36 | 3,919 | $334,272.49 | 68,052 | |
| Gollob Jared | KYMR | Chief Medical Officer | Mar 2, 2026 | Sell | $88.64 | 5,613 | $499,147.54 | 119,018 | |
| Booth Bruce | KYMR | Director | Mar 2, 2026 | Sell | $90.13 | 81,866 | $7,378,582.58 | 3,902,667 | |
| Jacobs Bruce N. | KYMR | Chief Financial Officer | Mar 2, 2026 | Sell | $88.64 | 7,576 | $673,709.54 | 234,472 | |
| Chadwick Jeremy G | KYMR | Chief Operating Officer | Mar 2, 2026 | Sell | $88.64 | 2,039 | $181,321.64 | 68,052 | |
| Mainolfi Nello | KYMR | Chief Executive Officer | Feb 25, 2026 | Sell | $91.65 | 30,000 | $2,707,812.59 | 676,431 | |
| Esposito Pamela | KYMR | Director | Feb 20, 2026 | Sell | $87.58 | 2,500 | $218,270.01 | 600 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-2.34%
$92.81
5D
-5.77%
$89.55
20D
-5.60%
$89.70
Price: $95.03 Prob +5D: 0% AUC: 1.000
0001193125-26-073386
8-K
false000181544200018154422026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026
KYMERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39460
81-2992166
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Kymera Therapeutics, Inc. 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 (Address of principal executive offices, including zip code)
(857) 285-5300 (Registrant’s telephone number, including area code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trade Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
KYMR
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 26, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2025 and for the fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Exhibits (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Kymera Therapeutics, Inc. on February 26, 2026, furnished herewith.
104
Cover Page Interactive Data
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Kymera Therapeutics, Inc.
Date: February 26, 2026
By:
/s/ Nello Mainolfi
Nello Mainolfi, Ph.D.
President and Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 13, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 13, 2026 · 100% conf.
AI Prediction SELL
1D
-2.34%
$92.81
5D
-5.77%
$89.55
20D
-5.60%
$89.70
Price: $95.03 Prob +5D: 0% AUC: 1.000
0001193125-26-011104
8-K
false 0001815442 0001815442 2026-01-13 2026-01-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2026
KYMERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39460
81-2992166
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Kymera Therapeutics, Inc.
500 North Beacon Street, 4th Floor
Watertown, Massachusetts 02472
(Address of principal executive offices, including zip code) (857) 285-5300 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trade Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
KYMR
The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 13, 2026, Kymera Therapeutics, Inc. (the “Company”) issued a press release announcing its preliminary cash balance as of December 31, 2025, a business update and further details on its 2026 key objectives and outlook. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company announced on January 13, 2025, that it estimates it had approximately $1.6 billion of cash, cash equivalents and marketable securities as of December 31, 2025. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the three months and year ended December 31, 2025. The audit of the Company’s consolidated financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information set forth above. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On January 13, 2026, the Company issued a press release outlining its key 2026 objectives and strategy to advance its leading portfolio of immunology programs. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Kymera Therapeutics, Inc. on January 13, 2026, furnished herewith.
104
Cover Page Interactive Data (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0001193125-25-263540
8-K
0001815442false00018154422025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025
KYMERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39460
81-2992166
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Kymera Therapeutics, Inc. 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 (Address of principal executive offices, including zip code)
(857) 285-5300 (Registrant’s telephone number, including area code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trade Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
KYMR
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 4, 2025, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Exhibits (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Kymera Therapeutics, Inc. on November 4, 2025, furnished herewith.
104
Cover Page Interactive Data
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Kymera Therapeutics, Inc.
Date: November 4, 2025
By:
/s/ Nello Mainolfi
Nello Mainolfi, Ph.D.
President and Chief Executive Officer
Latest Kymera Therapeutics Inc. News
KYMR Breaking Stock News: Dive into KYMR Ticker-Specific Updates for Smart Investing
Compare KYMR vs Leading Stocks
See how KYMR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KYMR Kymera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.